Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer by Ahn, Jeeyun et al.
355
Korean J Ophthalmol 2011;25(5):355-357
http://dx.doi.org/10.3341/kjo.2011.25.5.355 pISSN: 1011-8942 eISSN: 2092-9382
Case Report
Vortex Keratopathy in a Patient Receiving Vandetanib for 
Non-Small Cell Lung Cancer
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We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). 
A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both 
eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothe-
lial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 
OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. 
Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal 
corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in 
numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this 
corneal complication.
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Vortex keratopathy is characterized by distinctive bilateral 
corneal subepithelial whorls and is known to be associated 
with Fabry disease and the use of various drugs. Amiodarone, 
chloroquine, ibuprofen, indomethacin, naproxen, tamoxifen 
and chloropromazine are just a few of the wide array of medi-
cations that have been identified so far [1]. Herein, we report 
a case of vortex keratopathy in a patient treated with vandeta-
nib, a dual epidermal growth factor receptor (EGFR) and 
vascular endothelial growth factor receptor 2 (VEGFR2) in-
hibitor used in the treatment of non-small cell lung cancer 
(NSCLC).
Case Report
A 44-year-old woman was referred to the ophthalmology 
consultation service in October of 2009 for episodes of inter-
mittent blurred vision in both eyes. Her ophthalmic history 
was unremarkable. In January of 2009, the patient was diag-
nosed with NSCLC and after undergoing four cycles of com-
bined chemotherapy consisting of gemcitabine and cisplatin, 
she was enrolled in a clinical trial for vandetanib (ZD6474), a 
dual anti- EGFR and anti- VEGFR2 tyrosine kinase inhibitor. 
After six one-month cycles of vandetanib at 300 mg/day, the 
patient remarked that she felt as if a thin fog had spread in 
front of both eyes and she sought ophthalmologic evaluation.
On initial evaluation, her visual acuities were 20 / 20 OU. 
Intraocular pressures were normal in both eyes. Slit-lamp bi-
omicroscopy examination revealed diffuse subepithelial 
haze with inferior subepithelial whorls in both corneas (Fig. 1). 
No staining was observed with the application of fluorescein 
dye. The conjunctiva was quiet OU and both anterior cham-
bers were deep and clear. Irides, lens and fundus examina-
tions were unremarkable in both eyes and pupillary reaction 
and ocular motility were also normal. She had no previous 
use of medications known to be associated with vortex 
keratopathy.
Although we recommended artificial tear drops for symp-
tomatic relief, the patient felt no dryness in her eyes and 
wished to forgo the use of any topical medication. She was 
asked to return to our clinic 3-months later.
Discussion
This case demonstrated vortex keratopathy in both eyes 
while receiving vandetanib for the treatment of NSCLC. As Korean J Ophthalmol Vol.25, No.5, 2011
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Fig. 1. Photograph of the anterior segment of the right (A) and left (B) cornea of a patient who was treated with vandetanib. Subepithelial cor-
neal haze and whorls are observed.
far as we know, this is the first reported domestic case of van-
detanib-induced vortex keratopathy.
Vandetanib (ZD6474) is one of the novel ‘target therapies’ 
which inhibit signaling pathways involved in the develop-
ment and progression of cancer [2]. Specifically, it is the first 
protein tyrosine kinase inhibitor to target both EGFR and 
VEGFR2. EGFR is known to be over-expressed in the ma-
jority of NSCLC and to stimulate cell proliferation, survival, 
migration and angiogenesis [3,4]. VEGF is the target of nu-
merous antiangiogenesis drugs that seek to limit tumor 
growth by inhibiting the fundamental process of new blood 
vessel formation, an essential process for tumor expansion 
and metabolism.
Epidermal growth factor (EGF) is a small polypeptide that 
has potent stimulatory effects on epidermal cell proliferation 
and differentiation [5,6]. In the eye, EGF is one of the main 
growth factors involved in the maintenance of ocular surface 
homeostasis [7]. The molecule binds to the EGFR, which is 
localized in the basal cell layer of the conjunctiva and cornea, 
stimulates corneal epithelial cell proliferation and migration 
and is known to play a pivotal role in corneal wound healing 
[8-11]. Lacrimal EGF messenger RNA was found to be in-
creased in rabbits after corneal epithelial injury. Also, the or-
al administration of gefitinib (Iressa), an EGFR inhibitor, in 
rats demonstrated significant effects on the maintenance of 
normal corneal thickness, epithelial cell proliferation and 
stratification during corneal epithelial wound healing [12,13].
Reports of ocular complications arising from EGFR in-
hibitors include reversible recurrent corneal erosions, con-
junctival hyperemia, telangiectasia of the eyelid margins, 
meibomitis, tear film dysfunction, and tortuous eyelashes 
associated with gefitinib, corneal opacification in animals 
administered high doses of EGFR inhibitors and trichome-
galy and periorbital rash after erlotinib (Tarceva) use [14-17]. 
There have been only two reports of vortex keratopathy arising 
after EGFR inhibitor use, namely vandetanib and suramin, an 
antiparasitic medication that inhibits EGF, platelet-derived 
growth factor, and tumor growth factor-beta activity [18,19]. 
Discontinuation of suramin resulted in clearing of the cornea 
despite persistent corneal opacification and improvement in 
the patient’s ophthalmic symptoms was observed after van-
detanib dose reduction. Interestingly, the patient using van-
detanib had underlying epithelial basement membrane dys-
trophy and a history of recurrent corneal erosions, which may 
have predisposed her to the development of abnormalities in 
corneal epithelial wound healing [18].
Vortex keratopathy is characterized by a whorl-like pat-
tern of grayish golden-brown deposits in the corneal epi-
thelium [1]. Although the underlying pathogenesis is yet 
unclear, intralysosomal lipid-bearing inclusion bodies have 
been demonstrated in the corneal epithelium of both Fabry’s 
disease and various drug-induced vortex keratopathy cases 
[1,20]. Drug-induced vortex keratopathies typically share 
cationic and amphiphilic properties, allowing them to penetrate 
lysosomes and bind to cellular lipids, resulting in drug-lipid 
complexes which are believed to be the intralysosomal in-
clusion bodies observed in the basal layers of the corneal epi-
thelium [20,21]. On the other hand, biopsies of corneal lesions 
of suramin-induced vortex keratopathy reveal lysosomal ac-
cumulation of glycosaminoglycan [19]. As a biopsy was not 
performed in our patient, it remains unclear whether the 
cause for vortex keratopathy was epithelial deposition of 
vandetanib derived metabolites or defective epithelial turn-
over and migration due to EGFR inhibitory properties of the 
drug.
Although this patient did not undergo ophthalmological 
examination prior to the administration of vandetanib, we 
could not find any offending factor that could trigger such 
corneal changes as vortex keratopathy other than vandetanib. 
Stopping or reducing the dose of vandetanib would have 
provided better evidence for the establishment of a causal 
relationship between vandetanib use and vortex keratopathy. 
Nevertheless, it may be reasonable to assume that vortex 
keratopathy with subepithelial haziness was induced by 
vandetanib in this case.  
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by preferentially targeting cancer cells over normal cells, 
presumably resulting in better patient tolerability compared 
to cytotoxic drugs. However, it may be expected that sys-
temic complications will arise from the inhibition of specific 
signal transmission cascades and the recognition of these 
drugs as potential causes for such adverse reactions is neces-
sary in light of the expanding use of these drugs in the field of 
cancer treatment. Increased awareness regarding visual 
symptoms and regular ophthalmic examination should be 
deemed mandatory in patients receiving vandetanib for the 
treatment of various solid malignancies.
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